ArticleJournal of orthopaedic surgery and research2025
FTVI promotes osteogenic differentiation of bone marrow mesenchymal stem cells through LncRNA HIF1A-AS2.
Article in Journal of orthopaedic surgery and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectivesThe treatment of bone defects caused by trauma and pathological factors was a common problem in clinic. Extracorporeal fucosylation has been proved to promote osteogenic differentiation. Nevertheless, the biological processes by which they promote osteogenesis are currently poorly understood. Long non-coding RNAs (lncRNAs) were essential for controlling osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs). This study aimed to investigate whether LncRNA HIF1A-AS2 could mediate the effects of alpha-(1,3)-fucosyltransferase VI (FTVI) on osteogenic differentiation of BMSCs.
methodsRat BMSCs with lncRNA HIF1A-AS2 interference plasmid or the FTVI overexpression plasmid were co-cultured in osteogenic differentiation medium. The effects of fucosylation modification of FTVI on osteogenic differentiation of BMSCs were examined, with a focus on LncRNA HIF1A-AS2.
resultsFTVI could upregulate HIF1A-AS2, and inhibition of lncRNA HIF1A-AS2 in FTVI- transfected BMSCs could decrease type I collagen (Col I), runt-related transcription factor 2 (RUNX2), osteocalcin (OCN) and bone morphogenetic protein 2 (BMP2), vascular endothelial growth factor 165 (VEGF165) proteins expressions which were increased by FTVI. Furthermore, it was discovered that inhibiting lncRNA HIF1A-AS2 decreased the the homing ability of BMSCs demonstrating by antigen contents of HECA452 and CD15s.
conclusionsAccording to these results, the effects of FTVI on osteogenic differentiation of BMSCs depend on the existence of lncRNA HIF1A-AS2. A better understanding of the pathophysiological mechanism of bone defect helped to provide theoretical basis for the reconstruction of bone damage using stem cells in clinic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.